Sulfonylureas

What it is

Sulfonylureas are oral type 2 diabetes drugs that lower HbA1c by about 1% to 1.25% by increasing insulin release. They are one of the oldest glucose-lowering medicine classes, in use since the 1950s, and they are still prescribed because they are effective, widely available, and often less expensive than newer agents. Their main drawback is a higher risk of hypoglycaemia than many other non-insulin diabetes medicines, especially in older adults, people with kidney impairment, or when meals are skipped.

Common sulfonylureas include:

Generation	Examples	Notes
First generation	tolbutamide, chlorpropamide	Older drugs; chlorpropamide is no longer available in some countries such as the US
Second generation	glipizide, glyburide/glibenclamide, gliclazide, glimepiride	More commonly used; potency and hypoglycaemia risk differ

In India, sulfonylureas remain common in routine diabetes care because type 2 diabetes is highly prevalent and medication cost matters for many patients. They may be used alone or added to metformin or other medicines when blood glucose remains above target.

How it works

Sulfonylureas act on pancreatic beta cells. They bind to the sulfonylurea receptor on ATP-sensitive potassium channels, close those channels, depolarize the cell membrane, and trigger calcium entry. That calcium signal promotes insulin secretion.

The key point is that this insulin release is not fully dependent on current blood glucose level. Because of that, sulfonylureas can lower glucose effectively, but they can also cause blood sugar to fall too low, particularly if a person delays meals, exercises more than usual, drinks alcohol, or has reduced kidney or liver function.

They work best when the pancreas still has some insulin-producing capacity, so they are used for type 2 diabetes, not type 1 diabetes. Over time, as beta-cell function declines, their glucose-lowering effect may become less durable in some people.

Evidence and uses

Sulfonylureas are used to improve glycaemic control in adults with type 2 diabetes. They can be prescribed as monotherapy when metformin is not tolerated or contraindicated, or as combination therapy with metformin, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, or insulin in selected cases.

Important practical points include:

1. Effectiveness: As a class, they usually reduce HbA1c by about 1% to 1.25%.
2. Speed: They often lower glucose relatively quickly.
3. Cost: They are usually cheaper than many newer diabetes drugs.
4. Limitations: They can cause hypoglycaemia and modest weight gain.

Not all sulfonylureas are identical. Reviews and consensus papers note that some agents, especially glyburide/glibenclamide, are associated with more hypoglycaemia than agents such as gliclazide or glimepiride in many clinical settings. Choice of drug matters, especially in older adults and those with chronic kidney disease.

Cardiovascular safety has been debated for decades. Older studies raised concern that sulfonylureas might worsen cardiovascular outcomes, but more recent evidence suggests the class is heterogeneous and that risk may differ by individual drug, patient population, and comparator. Current evidence does not support treating all sulfonylureas as equally risky, but they are generally not chosen primarily for cardiovascular or kidney protection. If a person with type 2 diabetes also has established cardiovascular disease, heart failure, or chronic kidney disease, clinicians often consider agents such as SGLT2 inhibitors or GLP-1 receptor agonists because those classes have stronger outcome data for those conditions.

Sulfonylureas are still reasonable options when affordability, access, and HbA1c reduction are major priorities. In many Indian settings, that makes them a practical part of stepwise diabetes treatment, but the risk of low blood sugar should be discussed clearly.

Safety and interactions

The most important adverse effect is hypoglycaemia. Symptoms can include sweating, tremor, hunger, palpitations, confusion, blurred vision, drowsiness, or fainting. Severe hypoglycaemia is a medical emergency.

Other common or relevant safety issues include:

Safety issue	What to know
Hypoglycaemia	Risk is higher with missed meals, alcohol, older age, kidney disease, liver disease, and some longer-acting agents
Weight gain	Usually modest, but clinically relevant for some patients
Kidney impairment	Drug choice and dose may need adjustment; some agents are less suitable
Sulfa allergy	Cross-reactivity is not absolute, but history should be reviewed with a clinician
Overdose	Can cause prolonged, recurrent hypoglycaemia and needs urgent care

Drug interactions matter. Medicines that increase hypoglycaemia risk or alter sulfonylurea metabolism can make treatment less safe. Examples include some antifungals, certain antibiotics, warfarin, salicylates, and other glucose-lowering drugs. Alcohol can also increase the risk of low blood sugar, especially if food intake is poor.

People should take sulfonylureas exactly as prescribed and match dosing to regular meals. Do not double a missed dose unless a clinician has specifically advised how to handle missed tablets. If you have repeated low sugar episodes, new kidney problems, poor appetite, vomiting, or are fasting for illness or a procedure, contact your clinician or pharmacist promptly.

When to see a clinician

Seek medical advice if blood sugars remain high despite treatment, if you have repeated readings below 70 mg/dL, or if you have symptoms of hypoglycaemia. Urgent care is needed for severe confusion, seizure, loss of consciousness, or inability to swallow.

A medication review is also important if you are older, have chronic kidney disease, liver disease, irregular meal patterns, or are starting new medicines. Pregnant patients, people with type 1 diabetes, and those with recurrent severe hypoglycaemia need individualized management rather than routine sulfonylurea use.

Limitations and open questions

Sulfonylureas are effective, but they are not ideal for every person with type 2 diabetes. Their main limitations are hypoglycaemia risk, weight gain, and less durable glucose control in some patients as beta-cell function declines.

Evidence on cardiovascular outcomes is mixed and depends on which sulfonylurea is studied, what it is compared against, and the patient population. That means class-wide statements can be misleading. Human evidence supports their glucose-lowering effect well, but newer drug classes often have stronger evidence for heart and kidney outcomes.

Another open question in practice is how best to position sulfonylureas in lower-resource settings where cost and access strongly influence treatment choices. For many patients, they remain useful and evidence-based, but safer prescribing requires attention to the specific drug selected, kidney function, meal regularity, and education about hypoglycaemia.